# OnCo record paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016" ;
  schema:name "Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial"@en ;
  schema:description "Phase 2 or 3 results paper on Brentuximab vedotin in Hodgkin lymphoma, in The Lancet Oncology (2016), one of the most cited Europe PMC records with Brentuximab vedotin in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(16)30167-x>, <https://pubmed.ncbi.nlm.nih.gov/27451390/>, <https://europepmc.org/article/MED/27451390>, <https://clinicaltrials.gov/study/NCT02181738> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(16)30167-x> ;
  schema:datePublished "2016"^^xsd:gYear ;
  schema:author "Younes A, Santoro A, Shipp M, et al." ;
  onco:trials <https://onco.cc/trials/checkmate-205/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .